Anemia treatment in patients with chronic kidney disease

New England Journal of Medicine

Volumn 368, Issue 4, 2013, Pages 387-389

  Drüeke, Tilman B ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; HYPOXIA INDUCIBLE FACTOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINESATIDE; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DISEASE CLASSIFICATION; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HAZARD RATIO; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84872817399     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1215043     Document Type: Editorial

References (10)

1. Watson AJ. Adverse effects of therapy for the correction of anemia in hemodialysis patients. Semin Nephrol 1989;9:Suppl 1:30-4.
2. McMurray JJ, Parfrey PS, Adamson JW, et al. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012;2:1-335.
3. Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010;363:1146-55.
4. Lin RZ, Dreyzin A, Aamodt K, et al. Induction of erythropoiesis using human vascular networks genetically engineered for controlled erythropoietin release. Blood 2011;118:5420-8.
5. Bernhardt WM, Wiesener MS, Scigalla P, et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 2010;21:2151-6.
6. Macdougall IC. New anemia therapies: translating novel strategies from bench to bedside. Am J Kidney Dis 2012;59:444-51.
7. Macdougall IC, Rossert J, Casadevall N, et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med 2009;361:1848-55.
8. Macdougall IC, Provenzano R, Sharma A, et al. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med 2013;368:320-32.
9. Fishbane S, Schiller B, Locatelli F, et al. Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med 2013;368:307-19.
10. Jelkmann W. Biosimilar recombinant human erythropoietins ("epoetins") and future erythropoiesis-stimulating treatments. Expert Opin Biol Ther 2012;12:581-92.